GlassScriptPhysician profile
Ashleigh Brown
NPI 1972931061
$6,675.39
in general payments reported to CMS, 2019-2025
20 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $1,175 · 2023: $1,808 · 2024: $1,232 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,395 · Education: $8.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,394.51 |
| Education | $8.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,955.59 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $704.59 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $583.44 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $512.18 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $467.94 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $405.29 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $344.63 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $337.71 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $243.43 | 2021-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $236.81 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $210.41 | 2023-2025 | Auvelity |
| Alkermes, INC. | $207.25 | 2022-2025 | Aristada, Lybalvi |
| Eisai INC. | $160.52 | 2021 | |
| Corium, LLC | $104.00 | 2022-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $51.76 | 2022-2023 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $35.31 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Neos Therapeutics, LP | $33.69 | 2023 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $30.60 | 2021 | |
| Neurocrine Biosciences, INC. | $26.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.94 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.